Limited Capability for Testing <i>Mycobacterium tuberculosis</i> for Susceptibility to New Drugs
Hamzah Z. Farooq, Daniela María Cirillo, Doris Hillemann, David Wyllie, Marieke J. van der Werf, Csaba Ködmön, Vladyslav Nikolayevskyy
Abstract
We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.
Topics & Concepts
BedaquilineClofazimineTuberculosisMycobacterium tuberculosisLinezolidMedicineDrugMicrobiologyBiologyImmunologyPharmacologyLeprosyPathologyBacteriaGeneticsVancomycinStaphylococcus aureusTuberculosis Research and EpidemiologyMycobacterium research and diagnosisBiochemical and Molecular Research